Importance:Conduction system pacing (CSP) is a promising and potentially cost-effective alternative to biventricular pacing (BiVP) in patients with heart failure with reduced ejection fraction (HFrEF) and left bundle-branch block (LBBB), but its impact on heart failure (HF) outcomes remains uncertain. Objective:To compare CSP vs BiVP on an HF-related outcome in patients with HFrEF and LBBB. Design, Setting, and Participants:PhysioSync-HF (Conduction System Pacing Versus Biventricular Resynchronization in Patients With Chronic Heart Failure) was an investigator-initiated, multicenter, noninferiority randomized clinical trial enrolling participants from November 2022 to December 2023 with 12 months of follow-up at 14 hospitals across all regions of Brazil. Adults with symptomatic HFrEF (New York Heart Association NYHA] classes II through III), left ventricular ejection fraction (LVEF) of 35% or less, and LBBB (QRS duration ≥130 milliseconds) were eligible for inclusion. Data were analyzed from May to August 2025. Intervention:Patients were randomized 1:1 to either CSP (preferentially left bundle-branch area pacing) or BiVP. Main Outcomes and Measures:The primary outcome was a hierarchical composite of death, HF hospitalizations, urgent HF visits, and change in LVEF at 12 months. The prespecified noninferiority margin for the odds ratio (OR) was 1.2. Results:A total of 173 patients (median [IQR] age, 62 years [56-68]; 86 female patients [49.7%]; 115 (66.5%) with dilated cardiomyopathy; median [IQR] LVEF, 26% [22%-31%]; median [IQR] QRS, 180 milliseconds [170-200]) were included. At 12 months, CSP failed to meet noninferiority and was inferior to BiVP for the primary end point (OR, 2.36; 95% CI, 1.37-4.06; P = .99 for noninferiority; P = .002 for between-group difference). The time-to-event composite of death, HF hospitalizations, or urgent HF visits was higher in CSP (hazard ratio, 2.35; 95% CI, 0.99-5.61). Mean (SD) LVEF increased to 35% (12%) with CSP and 39% (12%) with BiVP (mean difference, 3.8%; 95% CI, 0.3%-7.3%). Relative to baseline, both groups had comparable improvements in QRS duration, Kansas City Cardiomyopathy Questionnaire Overall Summary Score, NYHA class, and natriuretic peptide levels. Total direct medical cost related to the procedure and heart failure care was the equivalent of $7090 (95% CI, $5779-$8648) lower in patients randomized to CSP at 12 months. Conclusions and Relevance:In patients with HFrEF and LBBB, CSP was inferior to BiVP for a composite of death, HF hospitalizations, urgent HF visits, and change in LVEF at 12 months. These findings do not support the routine use of CSP as the first-line resynchronization strategy in this population. Trial Registration:ClinicalTrials.gov Identifier: NCT05572736.
Background In low- and middle-income countries, reimbursement decisions often rely on projected incremental budget impact (IBI) analyses. We assessed whether drug incorporations into the Brazilian public health system (SUS) between 2012 and 2024 were consistent with affordability considerations within the health technology assessment (HTA) framework. Methods A retrospective documentary analysis was conducted using technical recommendation reports issued by the Brazilian National Committee for Health Technology Incorporation (Conitec). The primary variable was the total projected IBI of incorporated drugs. Subgroup analyses were performed by year of incorporation, health condition, and budget impact output. The proportion of total projected IBI relative to the Specialized Component of Pharmaceutical Care (CEAF) budget was assessed. Findings A total of 199 incorporated drugs were analyzed, 64 of which were projected to be cost-saving (Int$ 6·67 billion). These savings exceeded the total positive projected IBI generated by the remaining drugs (Int$ 4·05 billion). When COVID-19 vaccines were excluded, the cumulative projected IBI became positive, totaling Int$ 2·80 billion over the period analyzed, with sensitivity analyses yield estimates ranging from Int$ 2·36 billion to Int$ 2·88 billion. Preventable diseases exhibited the lowest median per capita IBI (Int$ 28; IQR Int$ 15; IQR Int$ 132), and oncological diseases the highest (Int$ 23,550; IQR Int$ 6789; IQR Int$ 57,154). Among drugs reimbursed exclusively by the Ministry of Health, the cumulative projected IBI represented 29% of the CEAF budget in 2024, exceeding 45% from 2019 to 2022. Interpretation The findings suggest that Conitec's decisions were consistent with HTA principles related to affordability. This interpretation is based on the evidence available at the time of the HTA decision rather than on observed real-world data following incorporation into the SUS. Funding None.
ABSTRACT Cardiac sarcoidosis (CS) is a potentially severe manifestation of systemic sarcoidosis, associated with advanced atrioventricular block, ventricular arrhythmias, heart failure, and sudden death. Diagnosis remains challenging due to phenotypic variability and the limitations of conventional diagnostic methods. Advances in imaging techniques, especially the combination of positron emission tomography/computed tomography (PET/CT) using 18F-FDG and cardiac magnetic resonance imaging (CMR), have revolutionized the diagnostic approach and therapeutic monitoring of CS. This article reviews current concepts of CS and its diagnosis, with a focus on the role of PET/CT, the importance of appropriate patient preparation, and integration with CMR.
Importance Bridging the low-density lipoprotein cholesterol (LDL-C) care gap in patients with established atherosclerotic cardiovascular disease (ASCVD) is challenging. Few quality improvement (QI) interventions have successfully improved patient care. Objective To evaluate the impact of a digitally enabled, multifaceted, QI intervention on the control of LDL-C concentration in patients with ASCVD. Design, Setting and Participants This was a pragmatic, 2-arm, cluster randomized clinical trial. A total of 28 clusters (public or private outpatient clinics) in Brazil were randomized to receive a digitally enabled QI intervention or routine practice (control). Adult patients (≥18 years) with established ASCVD were enrolled between November 2023 and December 2024 and followed up for 6 months. Intervention The intervention comprised a structured, digitally enabled QI strategy integrating previsit screening, electronic clinical decision support algorithms, audit and feedback mechanisms, and targeted clinician and patient engagement tools embedded within routine workflows to support lipid monitoring, treatment intensification, and adherence. Main Outcomes and Measures The primary outcome was mean LDL-C level at 6 months. Secondary outcomes included relative LDL-C change, achievement of LDL-C targets (<50 mg/dL and ≥50% reduction; to convert to millimoles per liter, multiply by 0.0259), and prescription of lipid-lowering therapies. All analyses were performed following the intention-to-treat principle and accounted for the cluster design by using a generalized estimating equations model. Results Among 1465 enrolled patients (mean [SD] age, 62.3 [10.1] years; 894 male [61.0%]; 714 intervention; 751 control), mean (SD) LDL-C concentration at 6 months was 76.3 (37.5) mg/dL in the intervention group and 85.6 (37.1) mg/dL in the control group. The adjusted mean difference was −6.62 mg/dL (95% CI, −11.11 to −2.13 mg/dL; P = .004). Patients in the intervention group were more likely to achieve an LDL-C concentration less than 50 mg/dL (23.5% vs 13.4%; odds ratio, 1.86; 95% CI, 1.30-2.65) and a 50% or greater reduction in LDL-C concentration (18.6% vs 13.4%; odds ratio, 1.76; 95% CI, 1.27-2.43). Prescription of intensive and combination lipid-lowering therapy was significantly higher in the intervention group. No significant differences in major cardiovascular events were observed. Conclusions and Relevance In this pragmatic cluster randomized clinical trial, a digitally enabled, multifaceted strategy produced modest LDL-C reduction and increased treatment intensification among patients with ASCVD. However, a proportion of patients had LDL-C levels that remained above recommended LDL-C targets, underscoring that the strategy tested was only partially effective in eliminating the residual care gap. Trial Registration ClinicalTrials.gov Identifier: NCT05622929
Background: Acute kidney injury (AKI) is a common and serious complication in critically ill patients with non-kidney organ dysfunction. Early prediction of AKI is crucial for timely intervention and improved outcomes. This study aimed to identify readily available non-renal predictors of AKI and to develop an exploratory prediction model in a specific cohort of critically ill patients with COVID-19-related septic shock requiring mechanical ventilation. Materials and methods: This was a single-center, observational, retrospective cohort study conducted in the respiratory ICU of Hospital H+ Querétaro between April and December 2020. The study included 42 mechanically ventilated patients with septic shock secondary to SARS-CoV-2 infection and non-kidney organ dysfunction. AKI was defined using the KDIGO criteria. Trend analysis, bivariate and multivariate linear regression, were used to identify predictors of AKI and severe AKI. Results: AKI occurred in 23 (54.8%) patients, with 6 (14.3%) developing severe AKI. Trend analysis revealed differences in norepinephrine dose, hemoglobin, and lactate trends between groups. A simplified logistic regression model, validated internally with bootstrapping to prevent overfitting, identified a protective trend associated with higher hemoglobin levels on admission. Quantitative analysis of a forecasting model for daily renal function showed moderate predictive accuracy. Conclusions: This study identified several readily available non-kidney organ dysfunction variables that can predict AKI and its severity in critically ill patients with COVID-19-related septic shock. These findings may help in the early identification of at-risk patients and facilitate timely interventions to potentially improve outcomes. Further validation in larger and more diverse populations is warranted.